Published in J Neuroimmunol on August 12, 2011
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology (2013) 3.02
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer (2014) 1.76
Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep (2013) 1.21
Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology (2012) 1.09
The immune reconstitution inflammatory syndrome related to HIV co-infections: a review. Eur J Clin Microbiol Infect Dis (2011) 0.99
PML-IRIS in a patient treated with brentuximab. Neurology (2012) 0.92
Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome. Brain (2013) 0.85
HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity. J Neurovirol (2013) 0.78
A case report of simultaneous PML-IRIS during corticosteroids tapering in a patient with an anti-synthetase syndrome. F1000Res (2013) 0.75
Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review. Front Immunol (2017) 0.75
Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet (1971) 11.92
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology (2009) 3.37
Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother (2005) 3.11
Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis (2009) 2.73
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology (1999) 2.49
Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol (1998) 2.02
Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med (2009) 2.02
Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy : pathogenesis, clinical manifestations and management. Drugs (2008) 1.95
Progressive multifocal leukoencephalopathy. Neurol Clin (1984) 1.92
Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr (2007) 1.82
Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology (2009) 1.81
Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology (1991) 1.78
Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol (2005) 1.77
Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol (2004) 1.60
Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol (1998) 1.43
Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol (2000) 1.40
Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol (2001) 1.36
Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci (2010) 1.28
The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol (2001) 1.26
Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr (2008) 1.24
The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol (2003) 1.23
Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology (2006) 1.19
Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol (2001) 1.07
Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology (1998) 1.07
Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol (2007) 0.94
Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. J Neuropathol Exp Neurol (2008) 0.87
A clue to the pathophysiology of posterior reversible encephalopathy syndrome. Arch Neurol (2010) 0.80
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology (2013) 3.02
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the medicare population. J Bone Joint Surg Am (2013) 2.24
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (2007) 2.09
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain (2004) 1.90
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia (2005) 1.86
Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol (2005) 1.81
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer (2014) 1.76
Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging (2010) 1.75
NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci (2008) 1.74
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry (2010) 1.73
Utility of molecular and serodiagnostic tools in cerebral toxoplasmosis with and without tuberculous meningitis in AIDS patients: A study from South India. Ann Indian Acad Neurol (2010) 1.72
HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A (2007) 1.71
Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol (2003) 1.70
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS (2002) 1.68
HIV-associated sensory neuropathies. AIDS (2002) 1.65
HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis (2009) 1.64
Evaluating sleep and cognition in HIV. J Acquir Immune Defic Syndr (2013) 1.64
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
The effects of hospital and surgeon volume on postoperative complications after LumbarSpine surgery. Spine (Phila Pa 1976) (2011) 1.61
Role of Tat protein in HIV neuropathogenesis. Neurotox Res (2009) 1.60
Dysphagia after anterior cervical decompression and fusion: prevalence and risk factors from a longitudinal cohort study. Spine (Phila Pa 1976) (2005) 1.58
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (2010) 1.56
Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read (2002) 1.56
Challenges to the diagnosis and management of HIV dementia. AIDS Read (2006) 1.55
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J Virol (2004) 1.52
Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology (2005) 1.51
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
Reproducibility of tDCS Results in a Randomized Trial: Failure to Replicate Findings of tDCS-Induced Enhancement of Verbal Fluency. Cogn Behav Neurol (2016) 1.47
Diagnostic utility of the subjective peripheral neuropathy screen in HIV-infected persons with peripheral sensory polyneuropathy. AIDS Read (2005) 1.46
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging (2004) 1.44
HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res (2003) 1.43
Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol (2002) 1.43
Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia (2008) 1.42
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis. Am J Pathol (2004) 1.40
Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol (2008) 1.40
Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse (2006) 1.40
The timing of surgical staging has a significant impact on the complications and functional outcomes of adult spinal deformity surgery. Spine J (2013) 1.39
Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol (2003) 1.39
Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology (2005) 1.39
Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem (2003) 1.38
Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G. J Neurovirol (2004) 1.38
Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci (2003) 1.35
HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res (2003) 1.34
Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab (2005) 1.33
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Reverse total shoulder replacement: intraoperative and early postoperative complications. Clin Orthop Relat Res (2008) 1.32
HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem (2003) 1.31
CXCL10-induced cell death in neurons: role of calcium dysregulation. Eur J Neurosci (2006) 1.31
HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem (2006) 1.31
HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci (2003) 1.29
The pathology of Rasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia (2004) 1.29
Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol (2005) 1.28
Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci (2010) 1.28
Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res (2003) 1.27
Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol (2004) 1.27
Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol (2011) 1.27
Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One (2012) 1.26
Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol (2011) 1.26
Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol (2010) 1.25
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol (2005) 1.23
Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J Med Res (2005) 1.23